- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Doxycycline Based Combination for Improving Clinical Outcomes across Spectrum of Covid-19 infections
The world continues to be amidst an unprecedented health crisis caused by the global spread of a novel coronavirus, SARS-CoV-2 which leads to respiratory, and multi-organ viral infection, termed as COVID-19. The pandemic has so far resulted in 35 million infections and more than one million mortalities 1 . It is noteworthy that almost all patients present initially with a mild- moderate disease; however, about 15% of them progress within 5-14 days post-infection to a more advanced stage of the disease, rendering them critical patients 2 . The highest risk patients seem to be elderly, obese, those suffering from type 2 diabetes, cardiovascular disease, and immunosuppressed.
In a scientific endeavour for clinically utilizing an effective therapy for COVID-19 patients - this recently published clinical trial is aimed to assess if doxycycline based combinational therapy can improve outcomes in treating COVID-19 infections, specifically including patients across the different clinical spectrum of disease. 3
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Doxycycline, click HERE
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751